Home › Inflammatory Bowel Disease › Maryland › Baltimore
Inflammatory Bowel Disease clinical trials in Baltimore, MD
6 studies for Inflammatory Bowel Disease are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
RecruitingPhase 4
- Johns Hopkins Bayview Medical Center, Baltimore
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RecruitingPhase 2
- Site 011, Glen Burnie · 9 mi away
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RecruitingObservational study
- Mercy Medical Center, Baltimore
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
RecruitingPhase 4
- The Johns Hopkins Children's Medical Center, Baltimore
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
RecruitingPhase 2
- Mercy Medical Center, Baltimore
Inflammatory Bowel Disease trials in other cities
- New York City, NY18 studies
- Boston, MA15 studies
- Miami, FL9 studies
- Seattle, WA9 studies
- Durham, NC8 studies
- Atlanta, GA8 studies
- Cincinnati, OH7 studies
- Washington, DC7 studies
- Orlando, FL7 studies
- Houston, TX7 studies
- Philadelphia, PA7 studies
- St. Louis, MO6 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer42 studies
- Lung Cancer40 studies
- Cancer (all types)38 studies
- Pancreatic Cancer32 studies
- Colorectal Cancer31 studies
- Metastatic Cancer28 studies
- Obesity25 studies
- Heart Failure24 studies
- Bladder Cancer24 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.